We are live on ! Find out more
BNTC icon

Benitec Biopharma
BNTC

21 hedge funds and large institutions have $2.44M invested in Benitec Biopharma in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 7 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more capital invested

Capital invested by funds: $2.09M → $2.44M (+$352K)

0.14% less ownership

Funds ownership: 2.59% → 2.45% (-0.14%)

16% less funds holding

Funds holding: 25 → 21 (-4)

80% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 5

86% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 7

Holders
21
Holders Change
-4
Holders Change %
-16%
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
7
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
+$9.75K
2
PAG
Private Advisor Group
New Jersey
+$3.15K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$77.5K
2
Renaissance Technologies
Renaissance Technologies
New York
-$36.1K
3
Walleye Capital
Walleye Capital
New York
-$30.7K
4
TSS
Two Sigma Securities
New York
-$9.36K
5
Jane Street
Jane Street
New York
-$4.67K

BNTC Hedge Fund Activity: Q1 2023 in Review

21 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q1 2023, worth a combined $2.44M — up 17% from $2.09M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of BNTC and 1 opened new positions — a net loss of 4 holders — while 7 trimmed existing stakes and 1 added.

The largest buyer was Virtu Financial, adding an estimated $9.75K. The largest seller was Morgan Stanley, cutting an estimated $77.5K.

  • 21 institutional investors held Benitec Biopharma (BNTC) as of Q1 2023, down from 25 in Q4 2022.
  • Funds reported $2.44M of Benitec Biopharma stock for Q1 2023, up 17% quarter-over-quarter.
  • 1 fund opened new Benitec Biopharma positions in Q1 2023 and 5 closed out, a net change of -4 holders.
  • The largest Benitec Biopharma buyer in Q1 2023 was Virtu Financial, an estimated $9.75K added.
  • The largest Benitec Biopharma seller in Q1 2023 was Morgan Stanley, an estimated $77.5K sold.

Based on aggregated 13F filings for Q1 2023.